Related Experiment Video

Updated: Jun 6, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
07:46

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat

Published on: June 4, 2012

Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus

W Poeppl1, S Tobudic, T Lingscheid

  • 1Department of Internal Medicine I, Division of Infectious Diseases, Medical University of Vienna, Vienna, Austria.

Antimicrobial Agents and Chemotherapy
|November 25, 2010
PubMed

Insights

Fosfomycin effectively treated experimental methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis in rats, significantly reducing bacterial bone infections. No resistance developed during the four-week study.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Orthopedics

Background:

  • Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of osteomyelitis.
  • Effective treatment options for MRSA osteomyelitis remain limited.
  • Fosfomycin is a broad-spectrum antibiotic with potential activity against MRSA.

Purpose of the Study:

  • To evaluate the efficacy of fosfomycin in a rat model of MRSA osteomyelitis.
  • To assess the development of antibiotic resistance during treatment.

Main Methods:

  • An experimental osteomyelitis model was established in rats using MRSA.
  • Rats were treated with daily intraperitoneal injections of fosfomycin (150 mg/kg) or saline placebo for four weeks.
  • Quantitative bacterial cultures of infected tibiae were performed post-treatment.

Main Results:

  • Fosfomycin treatment resulted in significantly lower rates of positive bone cultures compared to placebo (22.2% vs. 100%).
  • All untreated control rats had positive bone cultures for MRSA.
  • No development of fosfomycin resistance was observed after four weeks of treatment.

Conclusions:

  • Fosfomycin demonstrates significant efficacy in treating experimental MRSA osteomyelitis.
  • Fosfomycin is a promising therapeutic option for MRSA bone infections.
  • The 4-week treatment course did not induce resistance in MRSA.

More Related Videos

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds06:36

Improved Enzyme Protection Assay to Study Staphylococcus aureus Internalization and Intracellular Efficacy of Antimicrobial Compounds

Published on: September 8, 2021

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...